Pacific Biosciences of California 将来の成長

Future 基準チェック /16

Pacific Biosciences of California利益と収益がそれぞれ年間33.4%と19.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-33.7% 35.6%なると予測されています。

主要情報

33.4%

収益成長率

35.6%

EPS成長率

Life Sciences 収益成長	26.4%
収益成長率	19.5%
将来の株主資本利益率	-33.7%
アナリストカバレッジ	Good
最終更新日	12 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:P09 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	258	-169	-86	-43	12
12/31/2025	193	-202	-122	-108	14
12/31/2024	157	-359	-250	-184	14
9/30/2024	173	-394	-240	-233	N/A
6/30/2024	189	-400	-261	-253	N/A
3/31/2024	200	-297	-249	-240	N/A
12/31/2023	201	-307	-268	-259	N/A
9/30/2023	170	-309	-274	-262	N/A
6/30/2023	146	-319	-275	-260	N/A
3/31/2023	134	-321	-296	-279	N/A
12/31/2022	128	-314	-280	-263	N/A
9/30/2022	137	-299	-249	-234	N/A
6/30/2022	140	-206	-224	-212	N/A
3/31/2022	135	-175	-176	-167	N/A
12/31/2021	131	-181	-117	-111	N/A
9/30/2021	122	-37	-97	-94	N/A
6/30/2021	106	-77	-73	-71	N/A
3/31/2021	92	-59	-80	-79	N/A
12/31/2020	79	29	18	20	N/A
9/30/2020	80	-46	14	16	N/A
6/30/2020	83	-51	15	16	N/A
3/31/2020	90	-53	21	22	N/A
12/31/2019	91	-84	-81	-78	N/A
9/30/2019	82	-115	-82	-79	N/A
6/30/2019	79	-111	-78	-76	N/A
3/31/2019	76	-109	-76	-73	N/A
12/31/2018	79	-103	-68	-66	N/A
9/30/2018	84	-93	-71	-68	N/A
6/30/2018	89	-90	N/A	-71	N/A
3/31/2018	88	-93	N/A	-70	N/A
12/31/2017	93	-92	N/A	-68	N/A
9/30/2017	94	-90	N/A	-60	N/A
6/30/2017	96	-86	N/A	-58	N/A
3/31/2017	97	-79	N/A	-64	N/A
12/31/2016	91	-74	N/A	-68	N/A
9/30/2016	101	-57	N/A	-56	N/A
6/30/2016	90	-37	N/A	-56	N/A
3/31/2016	94	-31	N/A	-44	N/A
12/31/2015	93	-32	N/A	-48	N/A
9/30/2015	73	-49	N/A	-63	N/A
6/30/2015	80	-60	N/A	-53	N/A
3/31/2015	67	-67	N/A	-59	N/A
12/31/2014	61	-66	N/A	-51	N/A
9/30/2014	53	-64	N/A	-51	N/A
6/30/2014	40	-76	N/A	-26	N/A
3/31/2014	34	-77	N/A	-29	N/A
12/31/2013	28	-79	N/A	-30	N/A

アナリストによる今後の成長予測

収入対貯蓄率: P09今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: P09今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: P09今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: P09の収益 ( 19.5% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: P09の収益 ( 19.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: P09 3 年以内に赤字になると予測されています。

Pacific Biosciences of California 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022

Pacific Biosciences of California, Inc. Withdraws its Financial Guidance

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021

Recent updates

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023)

PacBio Unveils the Vega System

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems

Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024

President recently sold €155k worth of stock

Chief Operating Officer recently sold €57k worth of stock

Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024

Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023)

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions

Insider recently bought €162k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

President recently sold €445k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024

PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions

Chief Operating Officer recently sold €221k worth of stock

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

Third quarter 2023 earnings released: US$0.26 loss per share (vs US$0.34 loss in 3Q 2022)

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors

Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

President recently sold €918k worth of stock

Chief Operating Officer recently sold €263k worth of stock

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million.

Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.32 loss in 2Q 2022)

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.

Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Now 25% undervalued

Pacific Biosciences of California, Inc. Announces Board Changes

VP & Chief Accounting Officer recently sold €60k worth of stock

Insufficient new directors

Full year 2022 earnings released: US$1.40 loss per share (vs US$0.89 loss in FY 2021)

PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions

Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insufficient new directors

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022

Pacific Biosciences of California, Inc. Announces Board Appointments

Pacific Biosciences of California, Inc. Withdraws its Financial Guidance

Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022

PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing

Chief Financial Officer recently sold €75k worth of stock

PacBio Unveils A New Method for Comprehensive, Genome-Wide Tandem Repeat Analysis

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.21 loss in 2Q 2021)

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022

Pacific Biosciences of California, Inc. Appoints Jeff Eidel as Chief Commercial Officer, Effective August 16, 2022

Pacific Biosciences of California, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacific Biosciences of California, Inc. Announces Management Changes

First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.45 loss in 1Q 2021)

Insufficient new directors

Pacific Biosciences of California, Inc. to Report Q1, 2022 Results on May 04, 2022

Pacific Biosciences of California, Inc., Annual General Meeting, May 25, 2022

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Pacific Biosciences of California, Inc. to Report Q4, 2021 Results on Feb 15, 2022

Chief Operating Officer recently sold €519k worth of stock

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021

PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants

Insufficient new directors

Third quarter 2021 earnings released: EPS US$0.082 (vs US$0.14 loss in 3Q 2020)